Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
Cash Flows From Operating Activities | |||||
Net Income | 1,161,500 | 2,961,600 | 1,727,600 | 4,060,500 | 5,888,500 |
Depreciation Amortization | 526,300 | 638,000 | 1,117,000 | 457,200 | 680,600 |
Income taxes - deferred | -305,800 | -168,600 | -426,800 | 149,000 | 67,100 |
Accounts receivable | 61,300 | -203,400 | 324,800 | 2,800 | 68,800 |
Other Working Capital | -648,700 | -890,300 | -145,500 | -187,200 | 199,300 |
Other Operating Activity | 752,600 | -953,000 | 1,042,800 | -252,500 | 174,300 |
Operating Cash Flow | $1,547,200 | $1,384,300 | $3,639,900 | $4,229,800 | $7,078,600 |
Cash Flows From Investing Activities | |||||
PPE Investments | -277,000 | 342,300 | -258,100 | -424,800 | -514,500 |
Net Acquisitions | -6,138,000 | 990,300 | 28,100 | -1,006,500 | -120,700 |
Purchase Of Investment | -5,140,700 | -3,448,500 | -3,808,700 | -6,397,700 | -5,252,600 |
Sale Of Investment | 7,500,400 | 3,671,000 | 3,498,900 | 7,374,300 | 6,486,300 |
Purchase Sale Intangibles | -34,400 | -2,900 | -18,800 | -127,000 | -155,000 |
Other Investing Activity | -45,700 | 21,500 | -23,900 | -153,900 | -128,000 |
Investing Cash Flow | $-4,101,000 | $1,576,600 | $-563,700 | $-608,600 | $470,500 |
Cash Flows From Financing Activities | |||||
Debt Issued | 997,200 | 0 | 0 | 2,967,400 | 0 |
Debt Repayment | -809,900 | -1,002,200 | -170,000 | -1,500,000 | N/A |
Common Stock Issued | N/A | N/A | N/A | -4,600 | 0 |
Common Stock Repurchased | 0 | -750,000 | -1,800,000 | -6,679,100 | -5,868,300 |
Other Financing Activity | -38,000 | 4,900 | -116,200 | -56,400 | 7,900 |
Financing Cash Flow | $149,300 | $-1,747,300 | $-2,086,200 | $-5,272,700 | $-5,860,400 |
Exchange Rate Effect | 35,100 | -55,700 | -59,800 | 69,000 | 400 |
Beginning Cash Position | 3,419,300 | 2,261,400 | 1,331,200 | 2,913,700 | 1,224,600 |
End Cash Position | 1,049,900 | 3,419,300 | 2,261,400 | 1,331,200 | 2,913,700 |
Net Cash Flow | $-2,369,400 | $1,157,900 | $930,200 | $-1,582,500 | $1,689,100 |
Free Cash Flow | |||||
Operating Cash Flow | 1,547,200 | 1,384,300 | 3,639,900 | 4,229,800 | 7,078,600 |
Capital Expenditure | -277,000 | -240,300 | -258,100 | -424,800 | -514,500 |
Free Cash Flow | 1,270,200 | 1,144,000 | 3,381,800 | 3,805,000 | 6,564,100 |